CATALAYER NEWS
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL – Company Announcement - FT.com - Financial Times
Source: Financial Times · 2026-06-14
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL – Company Announcement - FT.com Financial Times
MORE FROM FINANCIAL TIMES
UK intercepts Russian shadow fleet oil tanker in English Channel - Financial Times
2026-06-14
How Israel’s ‘trampoline’ economy has adapted to war - Financial Times
2026-06-14
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a v
2026-06-14
Strawberry desserts that steal the spotlight - Financial Times
2026-06-14
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targe
2026-06-14
RELATED ON CATALAYER
Related Topics
EV & Auto Industry NewsRELATED MARKETS
Prediction Markets